Adam Finklestein has a bachelors in political science vs. Analyst David M. Nierengarten who has a PhD in BioChemistry from Berkeley... i think i will take my chances with the one that is educated in the field vs. the dork that writes columns for the street.
I will take my chances betting on this to go down because a BioChemist does not know as much as a Doctor who specializes in the endocrine system to include androgen receptors. The SARM developed by GTXI is not as effective as Oxandrolone. The SARM will also cost more. Wise up my friend or lose a lot of money.
Look at my post history... over $7 I was telling longs not to listen to people like you. I was correct and the fact is SAFETY issues will also come out in addition to the LACK of performance improvement. GTXI will have to show how the hearts androgen receptors are spared the SARM's effects. News flash they are not spared.... Also the company has not been straight up Oxandrolone is mostly anabolic just like a SARM. Oxandrolone is also now sold generically so why would insurance companies go with SARM's that do NOTHING more than Oxandrolone can already FACT.